Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)

Competing Interest Statement

A. Singleton and C. Blauwendraat are supported by the Intramural Research Program of the National Institute on Aging and have received grant support from the Michael J. Fox Foundation for Parkinson's Research and the Aligning Science Across Parkinson's Initiative. A. Singleton has received royalty payments related to a diagnostic for stroke. H. Leonard, H. Iwaki, D. Vitale, K. Levine and M. Nalls are consultants employed by Data Tecnica International. Data Tecnica is engaged in a consulting agreement with the US National Institutes of Health. H. Morris is employed by UCL. In the last 24 months, he reports paid consultancy from Biogen, Biohaven, Lundbeck; lecture fees/honoraria from Wellcome Trust, Movement Disorders Society; Research Grants from Parkinson's UK, Cure Parkinson's Trust, PSP Association, CBD Solutions, Drake Foundation, Medical Research Council, Michael J Fox Foundation. H. Morris is also a co-applicant on a patent application related to C9ORF72 Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140). B. Casey and J. Solle are employed by the Michael J. Fox Foundation for Parkinson's Research. All other authors declare no financial or non-financial competing interests.

Funding Statement

This research is supported by the Aligning Science Across Parkinson's Initiative, the Intramural Research Program, National Institute on Aging, National Institutes of Health, Department of Health and Human Services, project ZO1 AG000949, and the Michael J. Fox Foundation for Parkinson's Research. Data used in the preparation of this article were obtained from Global Parkinson's Genetics Program (GP2). GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and implemented by The Michael J. Fox Foundation for Parkinson's Research (https://gp2.org). For a complete list of GP2 members see https://gp2.org.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Global Parkinson's Genetics Program (GP2) is a collaborative effort whereby investigators around the world contribute anonymised clinical and genetic data from their Parkinson's cohort for use in joint analyses. Prior to an investigator contributing their cohort's data/samples, their consent documentation is reviewed by the GP2 Operations and Compliance Working Group to confirm that consent for data/sample sharing was provided, and material and data transfer agreements are signed between the investigator's institution and GP2. All contributing cohorts received ethical approval for their initial research study and obtained participant consent for sharing of data and samples. The entire dataset generated by GP2 will be made available to qualified researchers via the online repository AMP-PD. Three data releases are already available on AMP-PD, and data will continue to be released 2-4 times per year for the duration of the project. (https://www.amp-pd.org/federated-cohorts/gp2) Webpage for the GP2 Operations and Compliance Working Group: https://gp2.org/working-groups/operations-and-compliance-working-group/ GP2 contributing institutions: https://gp2.org/members/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes